ACRS Aclaris Therapeutics Potential Buyout
ACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025.
ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023.
ACRS reached 52 week low today: $5.05.
Analysts Price Targets:
$21 The Goldman Sachs Group
$29 BTIG Research
$38 Cantor Fitzgerald
$43 HC Wainwright
Considering the above, I think ACRS might be an easy +3X!
Looking forward to read your opinion about it.
ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023.
ACRS reached 52 week low today: $5.05.
Analysts Price Targets:
$21 The Goldman Sachs Group
$29 BTIG Research
$38 Cantor Fitzgerald
$43 HC Wainwright
Considering the above, I think ACRS might be an easy +3X!
Looking forward to read your opinion about it.
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.